Inside Allergan’s Upcoming Quarterly Earnings Release

S&P 500 (NYSE:SPY) component Allergan, Inc. (NYSE:AGN) will unveil its latest earnings on Wednesday, October 26, 2011. Allergan is a global specialty health care company. It discovers, develops, and commercializes innovative pharmaceuticals, biologics, and medical devices, as well as over-the-counter products.

Allergan, Inc. Earnings Preview Cheat Sheet

Wall St. Earnings Expectations: The average estimate of analysts is for net income of 90 cents per share, a rise of 15.4% from the company’s actual earnings for the same quarter a year ago. During the past three months, the average estimate has moved down from 91 cents. Between one and three months ago, the average estimate moved down. It has been unchanged at 90 cents during the last month. Analysts are projecting profit to rise by 15.2% versus last year to $3.64.

Past Earnings Performance: The company is looking to top estimates for the third straight quarter. Last quarter, it reported profit of 96 cents per share against a mean estimate of net income of 95 cents, and the quarter before, the company exceeded forecasts by 3 cents with profit of 77 cents versus a mean estimate of net income of 74 cents.

Investing Insights: has a Stock Chart Technical Analysts Dream About.

Wall St. Revenue Expectations: On average, analysts predict $1.33 billion in revenue this quarter, a rise of 9.9% from the year ago quarter. Analysts are forecasting total revenue of $5.42 billion for the year, a rise of 11.1% from last year’s revenue of $4.88 billion.

Analyst Ratings: Analysts are bullish on this stock with 14 analysts rating it as a buy, one rating it as a sell and seven rating it as a hold.

A Look Back: In the second quarter, profit rose 2.7% to $246.6 million (79 cents a share) from $240.1 million (78 cents a share) the year earlier, exceeding analyst expectations. Revenue rose 13.6% to $1.42 billion from $1.25 billion.

Key Stats:

Revenue has risen the past four quarters. Revenue rose 10.1% in the first quarter from the year earlier, climbed 6.9% in the fourth quarter of the last fiscal year from the year-ago quarter and 5.9% in the third quarter of the last fiscal year.

Competitors to Watch: Johnson & Johnson (NYSE:JNJ), Inspire Pharmaceuticals, Inc. (NASDAQ:ISPH), ISTA Pharmaceuticals, Inc. (NASDAQ:ISTA), Endo Pharmaceuticals (NASDAQ:ENDP), Medicis Pharmaceutical Corp. (NYSE:MRX), Akorn, Inc. (NASDAQ:AKRX), Novartis AG (NYSE:NVS), GlaxoSmithKline plc (NYSE:GSK), Merck & Co., Inc. (NYSE:MRK), and Hospira, Inc. (NYSE:HSP).

Stock Price Performance: During August 24, 2011 to October 20, 2011, the stock price had risen $8.68 (11.1%) from $77.90 to $86.58. The stock price saw one of its best stretches over the last year between March 31, 2011 and April 11, 2011 when shares rose for eight-straight days, rising 5.9% (+$4.19) over that span. It saw one of its worst periods between July 21, 2011 and July 27, 2011 when shares fell for five-straight days, falling 4.3% (-$3.60) over that span. Shares are up $18.04 (+26.3%) year to date.

(Source: Xignite Financials)

Investing Insights: has a Stock Chart Technical Analysts Dream About.